A5072802424- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- RNA and protein synthesis mechanisms
- Cancer Genomics and Diagnostics
- RNA Research and Splicing
- Evolution and Genetic Dynamics
- Computational Drug Discovery Methods
- Bioinformatics and Genomic Networks
- Heat shock proteins research
- vaccines and immunoinformatics approaches
- Veterinary Oncology Research
- AI in cancer detection
- Osteomyelitis and Bone Disorders Research
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Virus-based gene therapy research
- Spectroscopy Techniques in Biomedical and Chemical Research
- Molecular Biology Techniques and Applications
- Genomics and Chromatin Dynamics
- Sarcoma Diagnosis and Treatment
University Hospital Cologne
2024
University of Cologne
2023-2024
Objectives Owing to its highly infiltrative growth, feline injection-site sarcoma (FISS) carries a significant risk of local tumour recurrence. Parameters possible prognostic significance (eg, size and location, resection de novo vs recurrent tumours, achievement tumour-free surgical margins) were examined with regard their influence on recurrence rate (RR), disease-free interval (DFI) survival time (ST). Methods This was retrospective analysis cats FISSs located the chest or abdominal wall...
Abstract The emergence of resistance to targeted therapies restrains their efficacy. development rationally guided drug combinations could overcome this currently insurmountable clinical challenge. However, our limited understanding the trajectories that drive outgrowth resistant clones in cancer cell populations precludes design forestall resistance. Here, we propose an iterative treatment strategy coupled with genomic profiling and genome-wide CRISPR activation screening systematically...
<div>Abstract<p>The emergence of resistance to targeted therapies restrains their efficacy. The development rational-ly guided drug combinations could overcome this currently insurmountable clinical challenge. However, our limited understanding the trajectories that drive outgrowth resistant clones in cancer cell populations precludes design forestall resistance. Here, we propose an iterative treatment strategy coupled with genomic profiling and genome-wide CRISPR activation...
<p>Suppl. Table S6, Copy number from whole exome sequencing</p>
<p>Supplementary Methods, Figures and Tables</p>
<p>Suppl. Table S7, differentially expressed genes</p>
<p>Supplementary Note covering the mathematical modelling</p>
<p>Table S5 mutations from Whole exome sequencing</p>
<p>Suppl. Table S8, candidates from CRISPR activation screen</p>
<p>Supplementary Methods, Figures and Tables</p>
<p>Supplementary Note covering the mathematical modelling</p>
<p>Table S5 mutations from Whole exome sequencing</p>
<p>Suppl. Table S7, differentially expressed genes</p>
<p>Suppl. Table S6, Copy number from whole exome sequencing</p>
<p>Suppl. Table S8, candidates from CRISPR activation screen</p>
Stimulated Raman histology (SRH) is a label-free optical imaging method for rapid intraoperative analysis of fresh tissue samples. Analysis SRH images using Convolutional Neural Networks (CNN) has shown promising results predicting the main histopathological classes neurooncological tumors. Due to relatively low number rare tumor representations in CNN training datasets, valid prediction rarer entities remains limited. To develop new reliable tools, larger datasets and greater variety are...
<div>Abstract<p>The emergence of resistance to targeted therapies restrains their efficacy. The development rationally guided drug combinations could overcome this currently insurmountable clinical challenge. However, our limited understanding the trajectories that drive outgrowth resistant clones in cancer cell populations precludes design forestall resistance. Here, we propose an iterative treatment strategy coupled with genomic profiling and genome-wide CRISPR activation...
<p>Suppl. Table S8, candidates from CRISPR activation screen</p>
<p>Supplementary Methods, Figures and Tables</p>
<div>Abstract<p>The emergence of resistance to targeted therapies restrains their efficacy. The development rational-ly guided drug combinations could overcome this currently insurmountable clinical challenge. However, our limited understanding the trajectories that drive outgrowth resistant clones in cancer cell populations precludes design forestall resistance. Here, we propose an iterative treatment strategy coupled with genomic profiling and genome-wide CRISPR activation...
<p>Table S5 mutations from Whole exome sequencing</p>
<p>Supplementary Note covering the mathematical modelling</p>
<p>Supplementary Note covering the mathematical modelling</p>
<p>Suppl. Table S6, Copy number from whole exome sequencing</p>
<p>Suppl. Table S6, Copy number from whole exome sequencing</p>